OPORF - hVIVO plc
hVIVO plc
21 Plumbers Row
London E1 1EQ
United Kingdom
44 20 7756 1300
https://www.hvivo.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 210
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Yamin Mohammed Khan Ph.D. | CEO & Director | N/A | N/A | 1970 |
| Mr. Stephen Pinkerton | CFO & Exec. Director | N/A | N/A | 1965 |
| Mr. Andrew Catchpole | Chief Scientific Officer | N/A | N/A | N/A |
| Dr. Maurice N. Treacy Ph.D. | Chief Commercial Officer | N/A | N/A | N/A |
| Ms. Teja Marathe-Sarvadikar | Head of QA | N/A | N/A | N/A |
Description
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Corporate governance
hVIVO plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
